Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisinin-piperaquine tablets for untreated mild or common COVID-19
ChiCTR2000033049Phase 4Recruiting
- Sponsor
- Hongqi Hospital Affiliated to Mudangjiang Medical University
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dihydroartemisinin + piperaquine in coronavirus disease 2019 (COVID-19), sponsored by Hongqi Hospital Affiliated to Mudangjiang Medical University. Primary endpoints: Viral load of nCoV, Blood test and 12 more. Started May 2020; status: recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000033049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033049.